Kesimpta vs Ocrevus: Which Is the Better Option for Multiple Sclerosis Treatment?

 Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, disrupting communication between the brain and body. For patients living with MS, finding an effective and manageable treatment is crucial. Two commonly prescribed therapies—Kesimpta (ofatumumab) and Ocrevus (ocrelizumab)—are both disease-modifying therapies (DMTs) that aim to reduce the frequency of relapses and slow disease progression. But how do they compare?

What is Kesimpta?

Kesimpta is a targeted B-cell therapy approved by the FDA in 2020 for adults with relapsing forms of MS. It works by depleting specific B cells that are believed to contribute to the progression of MS. Kesimpta is unique in that it is self-administered via subcutaneous injection once a month, offering patients more flexibility and convenience.

What is Ocrevus?

Ocrevus, approved in 2017, is another B-cell depleting therapy indicated for both relapsing and primary progressive forms of MS. Unlike Kesimpta, Ocrevus is administered via intravenous infusion twice a year in a clinical setting. This makes it suitable for those who prefer less frequent dosing but are okay with clinic visits.

Kesimpta vs Ocrevus: Key Differences

When comparing Kesimpta vs Ocrevus, several factors come into play:

  • Administration: Kesimpta is self-injected at home, while Ocrevus requires biannual IV infusions at a healthcare facility.

  • Dosing Schedule: Kesimpta involves monthly injections; Ocrevus is taken every six months after the initial doses.

  • Side Effects: Both treatments can lead to infections due to immune suppression. However, Kesimpta may result in localized injection-site reactions, while Ocrevus users may experience infusion-related reactions.

  • Effectiveness: Both have shown high efficacy in reducing relapse rates and lesion activity. Individual results may vary depending on medical history, MS type, and other factors.

Safety and Monitoring

Because both medications affect the immune system, regular monitoring is required. Patients need periodic blood tests to check immune function and watch for signs of infection. Physicians also assess the long-term safety profile based on ongoing clinical research and patient feedback.

Cost and Insurance Coverage

Cost can be a deciding factor for many patients. Kesimpta vs Ocrevus are considered high-cost specialty drugs. Insurance coverage, co-pay assistance, and patient support programs may influence the final out-of-pocket expense. Discussing options with your healthcare provider and insurance representative is crucial.

Which One Should You Choose?

The choice between kesimpta and ocrevus should be based on your specific medical needs, lifestyle preferences, and treatment goals. Patients who prefer at-home treatment may find Kesimpta more convenient. On the other hand, those seeking fewer dosing sessions may lean toward Ocrevus.